|Awarded On||February 21, 2019|
|Title||Molecular Action of Phospho-BRD4–Targeting Compounds in Breast Cancer|
|Award Mechanism||Individual Investigator|
|Institution/Organization||The University of Texas Southwestern Medical Center|
|Principal Investigator/Program Director||Cheng-Ming Chiang|
*Pending contract negotiation
Treatment of breast cancer based on histological diagnosis and detection of molecular markers in cancer cells has been valuable in designing proper regimens for targeted therapy. Nevertheless, the clinical outcome remains uncertain due to the heterogeneity of tumor microenvironments and the genetic traits of individuals. Even though advanced sequencing technology has made it possible to profile an individual’s genome for personalized medicine, many cancer-driver genes and their expression patterns often exhibit an undetectable or minor difference between cancer and normal cells. This highlights the need for new diagnosis and prognosis strategies. Recently, two small compounds against the epi...